Antimicrobial activity of ceftolozane/tazobactam, imipenem/relebactam, and comparators against Gram-negative pathogens collected in Arabian Gulf countries: SMART 2020-2024.

Saved in:
Bibliographic Details
Title: Antimicrobial activity of ceftolozane/tazobactam, imipenem/relebactam, and comparators against Gram-negative pathogens collected in Arabian Gulf countries: SMART 2020-2024.
Authors: Wise MG; IHMA, Schaumburg, IL, United States., Alekseeva I; MSD, Dubai, United Arab Emirates., Siddiqui F; Merck & Co., Inc., Rahway, NJ, United States., Young K; Merck & Co., Inc., Rahway, NJ, United States., Motyl MR; Merck & Co., Inc., Rahway, NJ, United States., Sahm DF; IHMA, Schaumburg, IL, United States.
Source: Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2026 May 12; Vol. 16, pp. 1827575. Date of Electronic Publication: 2026 May 12 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Media SA Country of Publication: Switzerland NLM ID: 101585359 Publication Model: eCollection Cited Medium: Internet ISSN: 2235-2988 (Electronic) Linking ISSN: 22352988 NLM ISO Abbreviation: Front Cell Infect Microbiol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2235-2988
DOI:10.3389/fcimb.2026.1827575